Evidence map›Paper›PMID 38859783›Full record

ReviewCurrent pharmaceutical biotechnology2025

Phytoactive Molecules and Nanodelivery Approaches for Breast Cancer Treatment: Current and Future Perspectives.

Evren Algın Yapar, Merve Nur Ozdemir, Simona Cavalu, Özlem Akbal Dagıstan, Yıldız Ozsoy, Murat Kartal

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Evren Algın YaparDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Türkiye.ORCID 0000-0002-6504-4608
Merve Nur OzdemirDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Sivas Cumhuriyet University, Sivas, Türkiye.ORCID 0009-0002-3528-9716
Simona CavaluDepartment of Preclinical Sciences, Faculty of Medicine and Pharmacy, University of Oradea, Bihor, România.ORCID 0000-0001-7810-8925
Özlem Akbal DagıstanDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye.ORCID 0000-0002-6524-3535
Yıldız OzsoyDepartment of Pharmaceutical Technology, Faculty of Pharmacy, Istanbul University, Istanbul, Türkiye.ORCID 0000-0002-9110-3704
Murat KartalFaculty of Pharmacy, Bezmialem Vakıf University, Department of Pharmacognosy, Istanbul, Türkiye.ORCID 0000-0003-3538-2769

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most common malignancies in women, breast cancer accounts for nearly 25% of all cancer cases. Breast cancer is a diverse cancer form that exhibits variability in both morphology and molecular characteristics and is linked to numerous risk factors. Although various approaches and research are ongoing in the treatment and prevention of breast cancer, medication resistance in the current breast cancer treatment contributes to the disease's relapse and recurrence. Phytoactive molecules are the subject of growing research in both breast cancer prevention and treatment, but currently used conventional medicines and techniques limit their application. In recent years, significant advancements have been made in the field of nanotechnology, which has proven to be essential in the fight against drug resistance. The transport of synthetic and natural anticancer molecules via nanocarriers has recently been added to breast cancer therapy, greatly alleviating the constraints of the current approach. In light of these developments, interest in nano-delivery studies of phytoactive molecules has also increased. In this review, research of phytoactive molecules for breast cancers along with their clinical studies and nanoformulations, was presented from current and future perspectives.

Indexed as

Antineoplastic Agents, PhytogenicBreast NeoplasmsPhytochemicalsAnimalsAntineoplastic AgentsDrug Delivery SystemsFemaleHumansNanoparticlesAntineoplastic AgentsAntineoplastic Agents, PhytogenicPhytochemicalsbreast cancerclinical studiesnano drug deliveryphytoactive associated-nanocarriersPhytoactive moleculessurgery.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.